Louis G Lange's Net Worth
$23.9 Million
Who is Louis G Lange?
Louis G Lange has an estimated net worth of $23.9 Million. This is based on reported shares across multiple companies, which include GILEAD SCIENCES INC, Epiphany Technology Acquisition Corp., CymaBay Therapeutics, Inc., Esperion Therapeutics, Inc., BioPlus Acquisition Corp., Audentes Therapeutics, Inc., MAXYGEN INC, CV THERAPEUTICS INC, and NewAmsterdam Pharma Co N.V..
SEC CIK
Louis G Lange's CIK is 0001238401
Past Insider Trading and Trends
2007 was Louis G Lange's most active year for acquiring shares with 20 total transactions. Louis G Lange's most active month to acquire stocks was the month of November. 2007 was Louis G Lange's most active year for disposing of shares, totalling 27 transactions. Louis G Lange's most active month to dispose stocks was the month of November. 2009 saw Louis G Lange paying a total of $8,705,941.78 for 1,052,448 shares, this is the most they've acquired in one year. In 2020 Louis G Lange cashed out on 318,999 shares for a total of $15,947,940.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
GILEAD SCIENCES INC (GILD) Snapshot price: $78.52
EVP Cardiovascular Therapeutic
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Epiphany Technology Acquisition Corp. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
CymaBay Therapeutics, Inc. (CBAY) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 31
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Esperion Therapeutics, Inc. (ESPR) Snapshot price: $1.69
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 215.52K |
$14.00 |
—
| 215.52K |
Jul 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
BioPlus Acquisition Corp. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||